ProUroCare Medical, Inc. (OTCMKTS:PUMD) is a healthcare company focused on the development, commercialization and delivery of non-surgical medical technologies and therapies for urological and men’s health conditions. The company’s core offerings include low-intensity shockwave therapy systems designed to treat erectile dysfunction and Peyronie’s disease, as well as laser-based devices for addressing benign prostatic hyperplasia (BPH). In addition to hardware, ProUroCare Medical markets prescription-based injectable treatments and over-the-counter dietary supplements under its Pure Medical brand, targeting prostate health and sexual wellness.
Beyond product development, ProUroCare Medical supports independent urology and men’s health clinics through equipment installations, physician training and patient education programs. The company’s service model is aimed at streamlining adoption of its technologies in outpatient settings, enabling physicians to offer minimally invasive treatment options without the need for hospital-based equipment. This integrated approach seeks to enhance patient access to advanced therapies while allowing clinics to expand their treatment portfolios.
Founded in the mid-2010s, ProUroCare Medical is headquartered in Miami, Florida, and primarily serves the North American market. In recent years, the company has pursued distribution partnerships in select European and Latin American territories, with the goal of broadening its global footprint. ProUroCare Medical also explores collaborative research initiatives with academic medical centers to validate its therapeutic platforms and extend applications into related urologic disorders.
ProUroCare Medical’s management team combines expertise in medical device commercialization, pharmaceutical development and healthcare operations. The executive leadership includes a chief executive officer and chief medical officer with decades of collective experience in urology, complemented by executives overseeing regulatory affairs, clinical training and international business development. Together, they guide the company’s efforts to advance non-invasive treatment options for men’s health and urologic care.
AI Generated. May Contain Errors.
